KRAS and colorectal carcinoma: Thus, this concentration was used to assess the effect of drugs individually and in combination on cell proliferation employing four CRC cell lines, i.e., HCT116, RKO, HT29, and SW480, which exhibit different molecular backgrounds (p53, KRAS, BRAF, PIK3CA, JAK, STAT, HDAC mutations, and MSI status) summarized in Table S1.